The therapeutic strategy of blocking the SIRPα-CD47 interaction aims to enhance the immune system's ability to recognize and destroy cancer cells. By using monoclonal antibodies or small molecule inhibitors to disrupt this interaction, macrophages can be reactivated to phagocytose and eliminate tumor cells. This approach has shown promise in preclinical models and is currently being tested in clinical trials.
